Andrew Krouse, MALSPresident and CEO at Cavion, Inc.
Mr. Krouse has over a decade of biotech leadership experience as founder of Tau Therapeutics LLC, Xdynia LLC and the ventured-backed Cavion, Inc. In August 2019, Cavion, Inc. was acquired by Jazz Pharmaceuticals plc (Nasdaq: JAZZ). He has been recognized for his leadership in the industry as a CIT GAP 50 Entrepreneur in the Commonwealth of Virginia and as Chairman of the Board of the Virginia Biotechnology Association. Prior to joining the pharmaceutical industry, he worked in senior university leadership including as Vice President of the University of Virginia Darden School Foundation. He also previously served as an analyst at Goldman Sachs, NYC. In addition to his roles at Cavion, Inc. he serves on the boards of the Institute for Advanced Studies in Culture and the St. Anselm Institute for Catholic Thought, organizations promoting the intellectual community at the University of Virginia. He is a frequent speaker and published author with three patents in the T-type calcium channel space. Mr. Krouse is a cum laude finance graduate of the University of Maryland Business School. He received his MALS from Georgetown University and completed The Executive Program at the Darden Graduate School of Business Administration at the University of Virginia.